Eyedrop formulations are also very dependent on the target molecule so having a formulation that works does not necessarily mean success. This is the reason we also provide an intravitreal depot forming sustained release formulation. In this case we can very easily combine the target compound with an FDA approved polymer that can be injected into the vitreous. We have observed that the formulations stay at the injection site. Over a 24 hour period the polymer diffuses away leaving behind a depot of the drug. The drug slowly diffuses from the depot to the retina and can provide a sustained delivery for several days.
Preclinical Ophthalmic Contract Research